معرفی
Professor Kim Midwood serves as Professor of Matrix Biology and Kennedy Director of Graduate Studies at the University of Oxford's Kennedy Institute of Rheumatology, leading research on extracellular matrix dynamics in inflammatory diseases and cancer.
Her academic foundation includes:
- BSc (Hons) in Biochemistry from the University of Edinburgh (1995)
- PhD in Pathology from the University of Edinburgh (1999), investigating extracellular matrix changes in arthritis
Her research centers on matrix immunology, particularly tenascin-C's role in rheumatoid arthritis, tumor microenvironments, and fibrosis. She examines how tissue-specific matrix composition dictates immune cell behavior through toll-like receptor signaling and chemokine networks, revealing novel therapeutic targets for chronic inflammatory conditions.
Publications from 2013-2025 demonstrate evolving focus from arthritis mechanisms to broader applications in cancer immunotherapy and regenerative medicine, consistently highlighting matrix molecules as central regulators of disease progression.
Her accolades include:
- MRC New Investigators Award (2007)
- Arthritis Research UK Senior Fellowship (2012)
She directs the Matrix Immunology research group (established 2004 at Imperial College London, relocated to Oxford in 2011) and founded biotech company Nascient Ltd (2012) to translate matrix-targeting discoveries into clinical therapies.
